U.K. biotech company Harness Therapeutics has selected HRN001 as its lead experimental treatment candidate for Huntington’s disease. “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community,” Jan Thirkettle, PhD, CEO of Harness, said in a company press…
News
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has given Sarepta Therapeutics the go-ahead to start a first-in-human Phase 1 clinical trial of its investigational therapy SRP-1005 for Huntington’s disease. Sarepta plans to start the trial, dubbed Study SRP-1005-101 or INSIGHTT, between April and June, according to a…
Nine months of treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 appears to have slowed disease progression relative to its natural course in people with early-stage Huntington’s disease. That’s according to new interim data from a substudy, or Part C (ACTRN12624000602527), of an Australia-based Phase 1 clinical trial…
Comedian and actor Will Forte is teaming up with Teva Pharmaceuticals to raise awareness about Huntington’s disease (HD). Forte has signed on as an ambassador for Teva’s Honestly HD campaign, sharing his family’s story with Huntington’s in hopes of offering resources…
Ingrezza (valbenazine) engages with its VMAT2 target more strongly than extended-release Austedo XR (deutetrabenazine), which may translate into better control of chorea by more effectively reducing excess dopamine, the cause of these uncontrolled movements in Huntington’s disease and tardive dyskinesia, according to a study. Both medications are…
Loqus23 Therapeutics said it is advancing LQT-23 for development as a first-in-class oral treatment for Huntington’s disease. The company said LQT-23 has the potential to slow or halt the onset and progression of the disease, and it plans to submit applications seeking permission to bring the experimental therapy…
The team at Huntington’s Disease News covered the latest community developments and updates in research related to Huntington’s disease throughout 2025. We’ve compiled a list of the top five most-read articles we published in 2025. We look forward to continuing to serve the Huntington’s community in the years to come…
Disruption of lysosomal quality control — a system that keeps lysosomes, the cell’s waste-disposal units, working properly — may contribute to the development of Huntington’s disease, according to a study in cell and mouse models of the disease. Lysosomal quality control, or LQC, typically helps nerve cells repair or…
The California Institute for Regenerative Medicine (CIRM) — a state agency created to advance novel treatments for serious medical conditions — has granted nearly $12 million in funding to support a first-in-human clinical trial that will test a stem cell therapy candidate for Huntington’s disease. The grant was…
Certain antipsychotic medications, including the Huntington’s approved therapy tetrabenazine (sold as Xenazine in the U.S., with generics available), significantly improve functional capacity in people with Huntington’s disease. That’s according to data from a one-year, Phase 3 clinical trial in France called NEUROHD (NCT00632645), which compared the benefits…
Recent Posts
- Tiny systems that keep my life moving with Huntington’s disease
- UK company selects HRN001 as its lead Huntington’s therapy candidate
- Giving thanks for the brave volunteers who participate in HD clinical trials
- The challenges of navigating dating while living with Huntington’s disease
- Guest Voice: I hate Huntington’s disease, but I love my husband